Novel Radiotheranostic Ligands Targeting Prostate-Specific Membrane Antigen Based on Dual Linker Approach
Molecular Pharmaceutics · 06.01.2025 · 22 (1) · 377-386
DOI: 10.1021/acs.molpharmaceut.4c00974 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 30.11.2024. Verfasst von Nobuki Kazuta und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. Hauptthemen laut MEDLINE: Glutamate Carboxypeptidase II, Prostatic Neoplasms, Antigens, Surface, Radiopharmaceuticals. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Support for Pioneering Research Initiated by the Next Generation.
Abstract (Originalsprache)
Radiotheranostics using prostate-specific membrane antigen (PSMA)-targeting radioligands offers precision medicine by performing radionuclide therapy based on results of diagnosis. Albumin binder (ALB) binds to albumin reversibly and contributes to effective radiotheranostics by enhancing tumor accumulation of PSMA-targeting radioligands. We newly developed two ALB-containing PSMA-targeting radioligands including dual functional linkers, a hydrophilic linker, d-glutamic acid, and a hydrophobic linker, 4-(aminomethyl)benzoic acid, with the opposite arrangement (PNT-DA6 and PNT-DA7). A biodistribution study of [111In]In-PNT-DA6 indicated that the introduction and arrangement of dual functional linkers contributed to improved pharmacokinetics. A single photon emission computed tomography study of [111In]In-PNT-DA6 produced a clear PSMA-expressing tumor image. Moreover, [225Ac]Ac-PNT-DA6 showed the inhibition of tumor growth in targeted radionuclide therapy in PSMA-expressing tumor-bearing mice. These results indicated that [111In]In-PNT-DA6 and [225Ac]Ac-PNT-DA6 exhibited useful characteristics as PSMA-targeting radiotheranostic ligands.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan.
- Research Center, Nihon Medi-Physics Co., Ltd., 3-1 Kitasode, Sodegaura-shi, Chiba 299-0266, Japan.
ORCID-Profile: Kazuma Nakashima, Hiroyuki Watanabe, Masahiro Ono
Förderung
- Japan Agency for Medical Research and Development
- Support for Pioneering Research Initiated by the Next Generation
Zitieren
APA
Kazuta, N., Nakashima, K., Tarumizu, Y., Sato, T., Maya, Y., Watanabe, H., & Ono, M. (2025). Novel Radiotheranostic Ligands Targeting Prostate-Specific Membrane Antigen Based on Dual Linker Approach. Molecular Pharmaceutics, 22(1), 377-386. https://doi.org/10.1021/acs.molpharmaceut.4c00974
Vancouver
Kazuta N, Nakashima K, Tarumizu Y, Sato T, Maya Y, Watanabe H, et al. Novel Radiotheranostic Ligands Targeting Prostate-Specific Membrane Antigen Based on Dual Linker Approach. Molecular Pharmaceutics. 2025;22(1):377-386. doi:10.1021/acs.molpharmaceut.4c00974
BibTeX
@article{Kazuta2025,
author = {Kazuta, Nobuki and Nakashima, Kazuma and Tarumizu, Yuta and Sato, Takumi and Maya, Yoshifumi and Watanabe, Hiroyuki and Ono, Masahiro},
title = {Novel Radiotheranostic Ligands Targeting Prostate-Specific Membrane Antigen Based on Dual Linker Approach},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {1},
pages = {377--386},
doi = {10.1021/acs.molpharmaceut.4c00974}
}
EUVIMED